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The Mediterranean variant of glucose-6-phosphate dehydrogenase (G6PD) is functionally deficient and
found in a variety of cell types of affected individuals, including both erythocytes and neutrophils. To
determine if the presence of this sex-linked gene is associated to any degree with the occurrence of severe
bacterial infection, a study of hospitalized male patients in Iran was undertaken. As determined by
erythrocyte assay, allele prevalence in male patients with infection was 22% vs. 12% in a patient group
matched for the absence of other risk factors for infection and 6% in a second group who had additional risk
factors for infection. When the control and patient groups were considered together the difference between
the frequency of G6PD deficiency (10.2%) was significantly different from that found in the infected patients
(p < .05). Furthermore the mean age of infected patients with G6PD deficiency was significantly less than
that of infected patients without G6PD deficiency or non-infected control groups. These data suggest that
host defenses may be altered in G6PD deficiency so that bacterial infections are more severe. Alternatively,
G6PD deficiency and infection might represent concomittant risk factors which lead to hospitalization
during bacterial infection. Potential mechanisms by which host defenses might be altered in G6PD
deficiency are discussed.
Glucose-6-phosphate dehydrogenase (G6PD) is a cytoplasmic enzyme which
catalyzes the conversion of glucose-6-phosphate to 6-phosphogluconolactone. This
reaction which requries NADP' as a cofactor, is the rate limiting step in the
operation of the so-called pentose shunt, an enzymatic system found in almost all
human cell-types. Besides the formation of five-carbon sugars, the products of
pentose-shunt activity include NADPH and CO2 [1]. In erythrocytes, pentose-shunt
activity is linked to a recycling of oxidized to reduced glutathione, through the
provision of NADPH; and plays an important role in the antioxidant defenses of
these cells [2]. G6PD activity is a sex-linked trait with a number ofvariant types and
isoenzymes described, some of which are pathogenetically important because of
decreased activity. G6PD Mediterranean is the name given to an enzyme type found
in certain percentages ofMediterranean, Middle Eastern and Far Eastern population
groups. In contrast to other G6PD types, it is unique both for its markedly reduced
activity and its wide distribution among a variety of cells, including granulocytes
[1,3,4].
Individuals with G6PD Mediterranean may experience severe hemolysis when
exposed to certain oxidants orthe oxidant stress ofinfection[5]. Furthermore, severe
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All rights of reproduction in any form reserved.deficiencies of granulocyte G6PD activity (< 5%) may be associated with repetitive
bacterial infections and an inability to kill catalase-positive microorganisms [6-8].
The mechanism for this microbicidal defect appears to lie in a failure to form
adequate amounts of superoxide and H202 from molecular oxygen during phagocy-
tosis, through the action ofan oxidase which utlizes NADPH as a substrate[9]. Such
severe deficiencies are unusual, however, and in most studies the degree of granulo-
cyte G6PD activity in G6PD Mediterranean averages between 25 to 33% of normal
[3,4]. Even so it is possible that such neutrophils may be less able to withstand
oxidant stresses and to detoxify H202 formed during phagocytosis because of
depleted intracellular GSH stores [9]. Evidence exists that depletion ofintracellular
GSH in granulocytes may impair critical events in normal motility responses such as
the assembly of microtubules [10,11] and the H202 accumulation may be a mechan-
ism of cell death during phagocytosis [12]. With these points in mind an increased
susceptibility to bacterial infection in patients with Mediterranean G6PD might
occur either because of intravascular hemolysis leading to a functional blockade of
the reticuloendothelial system as suggested by Kaye et al. [13] or because ofabnormal
leukocyte function or both.
Although several individual patients with G6PD Mediterranean have been de-
scribed whose susceptibility to infection could be traced directly to defective
neutrophil bactericidal function, no information is available as to the relevance ofthe
other postulated mechanisms. Furthermore, data from population studies on the
relative incidence and prevalence of bacterial infections as a function of G6PD
activity is scanty and incomplete. As a prelude to further in vitro studies and in an
attempt to determine if the presence of Mediterranean G6PD might alter susceptibil-
ity to infections, a study of hospitalized patients in Shiraz, Iran, was undertaken.
MATERIALS AND METHODS
Performance Site and Initial Patient Selection
This study was carried out over a three-month period (May-July 1976) in Shiraz,
Iran, at Nemazee and Saadi Hospitals, two teaching hospitals affiliated with Pahlavi
University Medical School. All subjects were Iranian males and all, except one,
inpatients at one of these hospitals. Males were chosen since they would be either
G6PD deficient or normal.
Collection ofDemographic Data
Approximately three times per week charts were reviewed ofall adult male patients
in Nemazee Hospital and from the medical, orthopedic, and neurosurgical wards in
Saadi Hospital. Charts of male pediatric patients were also reviewed during the last
month of the study. The data collected included age, place of origin, history of
present illness, past medical history, family history, physical examination findings,
laboratory data, procedures performed, and hospital course. When necessary, patient
information was also obtained from responsible medical personnel. Complete
records of all the demographic parameters could be obtained on over 95% of the
patients by these means.
Collection ofData Regarding Infection
The diagnosis of infection was established by one or more of the following
methods: cultures, specific antibody titers, biopsies, X-rays, examination of inflam-
matory effusions and, finally, response to therapy with specific antimicrobials.
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Depending upon the specificity of the findings used to establish the etiologic agent,
infected patients were placed into two groups as described below.
Patient Exclusions
As far as possible all individuals with systemic diseases other than G6PD
deficiency or therapy which might predispose in some way to bacterial infection were
excluded from study. Diagnoses in the excluded group included patients with
malignancy, diabetes mellitus, cirrhosis, renal failure, cardiac failure, sickle cell
anemia, thalassemia, malaria, echinococchosis, viral infections, tetanus, open
trauma, renal stones, and vasculitis. Patients receiving glucocorticoids orin whom no
diagnosis of a specific disease could be made were also excluded. When patients with
any of these conditions were studied before a precise diagnosis was made, they were
placed into a separate group for data analysis as noted below.
Definition ofInfected Patient Groups
All patients with bacterial infections and no known predisposing reason for
infections other than possible G6PD deficiency were placed into the infected group.
In cases where the etiologic agent was definitely established by culture results,
diagnostic antibody titers, or biopsy findings the patients were categorized as "Class
1." Patients in whom a bacterial etiology for infection was highly suspected but not
definitely proven were placed in "Class 2." Class 2 patients included those with a
combination of X-rays consistent with pneumonia or tuberculosis, inflammatory
responses in body fluids or biopsies consistent with pyogenic or tuberculous
infection, clinical symptoms characteristic of bacterial infection, and a response to
antimicrobial therapy. One patient in the infected group was seen at the Nemazee
Outpatient Clinic. Brucella agglutinin titers were diagnostic of infection with this
organism and it was elected to treat him at home rather than in the hospital.
Definition of Control Groups
Those male patients free of diseases known to be associated with infection or
G6PD deficiency were designated as control group "A." Control group "B" patients
consisted ofindividuals without defined infection who were tested before a definitive
clinical diagnosis was available. All of these patients had a variety of potentially
predisposing factors to infection, or syndromes which mimic bacterial infections in
some of their features (e.g., fever).
G6PD Assays
Measurement of erythrocyte G6PD activity was carried out as follows: for each
assay, approximately 5 cc ofblood was drawn into a syringe, transferred immediately
to a Vacutainer tube containing EDTA, and mixed well. Bloods were refrigerated at
4°C within 15 minutes and were tested within three days with the semiquantitative
method developed by Sigma (Technical Bulletin No. 400). Kit instructions were
followed exactly, including appropriate compensation for the degree of anemia
present. In this assay, erythrocytes are lysed by water to release G6PD. This solution
is then added to glucose-6-phosphate and NADP in the presence of phenazine
methosulfate, an electron carrier, and dichlorophenol indophenol, a blue dye. The
NADPH formed during the oxidation of glucose-6-phosphate to 6-phosphogluco-
nate reduces the dye to a colorless form, and the rate of the reaction can be followed
visually. The tubes are observed for a six-hour period. For a minority ofpatients the
quantitative test for G6PD activity performed in the Nemazee Hospital Laboratory
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(Brilliant Cresyl Blue Reduction, Dade, Miami, CA) was used. In these cases, only
samples with 0% activity were considered deficient.
Grouping of Data and Statistical Analysis
Statistical significance of differences in rates of G6PD deficiency were determined
by the chi-square method of analysis. Infected patients were compared with control
"A" and control "A" plus control "B." No separate comparisons with control "B"
were made, because of the small number of subjects. Subgroups of patients matched
exactly for age and origin were analyzed in a similar way. Those infected patients in
whom an etiologic agent was established were divided according to whether the agent
contained catalase or was catalase negative. The catalase positive group was
compared with controls, but the catalase negative group was too small to permit
statistical analysis. The unpaired "t" test was used to analyze the mean age difference
between the G6PD normal and the G6PD deficient infected groups. With both the
chi-square and the unpaired "t" test, p < .05 was considered statistically significant.
RESULTS
Assay Validity
Before conducting the studies in Iran, assays were run at Yale University School of
Medicine using blood samples tested quantitatively by the Yale-New Haven Hospital
laboratories. The age of the samples ranged from two hours to eleven days. Samples
of all ages with normal G6PD activity decolorized within one hour, and sampleswith
10 percent activity decolorized in two to two and a half hours, consistent with data
obtained by Sigma.
In Iran, an effort was made to study all infected patients as soon as possible after
admission, usually within a few days. It was not always feasible to carry out the
assays when no medications were being given; however, a complete list of drugs that
each patient was receiving was compiled, and no agents that might have affected the
assay were present in the study group. Fourteen of our seventeen abnormal samples
had not decolorized at 6 hours, indicating very severe deficiency. Two of the
remaining three took 3 hours but when repeated took 4 hours or more, and the third
took 4½/2 hours but could not be repeated. Of the fourteen that took more than 6
hours, 5 were randomly repeated and all confirmed the original result; in two cases
the assay was performed within 2 hours ofthe time the blood was drawn. Three ofthe
normal assays were repeated and confirmed.
Patient Characteristics
The demographic characteristics of all patients are presented in Table 1. The
average age of the 55 infected patients was 31 years; the G6PD normal group differed
substantially from the G6PD deficient group, 34 years compared to 22. This
difference was statistically significant (.001 <p < .005). There were 65 control "A"
patients, with an average age of34 years, and 33 control"B" patients, with an average
age of 38 years. In these two groups there was no difference between theproportions
of G6PD normal and G6PD deficient patients. The distribution between those from
villages and from major cities was relatively even, although a somewhat greater
proportion ofthe control "A" group came from the cities. Ofthe city patients, atotal
of seven camefrom places other than Shiraz(three infected patients and three control
"B" patients, one each from Yazd, Teheran, and Mashad, and one control "A"
patient from Yazd). It seems reasonable to assume that villagers are less likely to
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TABLE I
Patient Demographic Data
Number Average Origin
Category of Patients Age (Range) Village Citya Nomad Not Known
G6PD nl 43 34(8-85) 22 14 1 6
Infected G6PD def 12 22 (11-35) 8 3 0 1
Total 55 31 ( 8-85) 30 17 1 7
G6PD nl 57 34 (14-70) 28 28 0 1
Control G6PD def 8 37 (22-55) 6 1 1 0
Total 65 34 (14-70) 34 29 1 1
G6PD nI 31 38 (15-80) 18 10 0 3
Control G6PD def 2 39 (18-60) 2 0 0 0
Total 33 38 (15-80) 20 10 0 3
aShiraz, Teheran, Isfahan, and Mashad
travel, and that therefore an even smaller percentage is from outside the Shiraz area.
The criteria by which infections were established are listed in Table 2, and the
actual diagnosis in Table 3. Table 4 contains the diagnosis ofcontrol"A" and control
"B," respectively. Some of the patients had a history of a disease other than that for
which they were admitted to the hospital. Of the infected patients, three had a past
history of typhoid (the present illnesses were two with pneumonia and one with
osteomyelitis), one had psoriasis(shigellosis), and one had hypertension (meningitis).
TABLE 2
Diagnostic Criteria in Infected Patients
Class 1: Diagnosis Criterion for Diagnosisa
Pneumococcal infection Culture
Staphylococcal sepsis Culture
Streptococcal meningitis Culture
Shigellosis Culture
Anthrax Culture
Brucellosis Titer
Typhoid Titer
Tuberculosis Biopsy
Actinomyces Israelii
abscess Biopsy
Class 11: Diagnosis Criteria for Diagnosisa
Pneumonia Chest X-ray and response to antibiotics
Meningitis Cerebrospinal fluid findings and response
to antibiotics
Osteomyelitis X-ray or biopsy
Tuberculosis Chest X-ray
Erysipelas Response to antibiotics
Brain abscess Cerebrospinal fluid findings plus air
fluid level on skull X-rays
Pyopneumothorax Pus in pleural fluid
aln all cases, clinical symptoms were also compatibleTABLE 3
List of Infected Patients by Diagnosis
Number of Number
Diagnosis Patients Deficient
Osteomyelitis 12 2
Tuberculosis 9 I
Pneumoniaa 8 4
Brucellosis 6 2
Staphylococcal septicemia 3 2
Meningitisb 3
Typhoid 3 0
Anthrax 3 0
Shigellosis 3 0
Erysipelas I 0
Pyelonephritis I 0
Pyopneumothorax I 0
Brain abscess I 0
Extradural abscess I 0
55 12
aln 2 cases, one of which was G6PD deficient, the etiologic agent was determined by culture to be pneumococcus.
bln I case, which was G6PD normal, the etiologic agent was determined by culture to be hemolytic streptococcus.
Of the control "A" patients, one had had typhoid (snake bite), one had had malaria
(upper gastrointestinal tract bleed), and one had had an ulcer (low back pain); of
control "B" patients, one had rheumatoid arthritis (and was on steroid therapy) and
one had had smallpox (diagnosis of present illness not made).
The results of the G6PD assays are in Table 5. Twenty-two percent of the infected
patients were G6PD deficient, compared to twelve percent of control "A" and six
percent of control "B" (Table 5a). Tables 5b, 5c, and 5d show the rates of G6PD
deficiency in three subgroups, one with matched ages, one with matched origins
(villagers only), and one selected on the basis of whether the etiologic agent was
catalase positive or catalase negative. Matching for age was important from two
aspects: older patients might have a lower frequency of G6PD deficiency if the gene
causes an increase in mortality rates and older patients have a naturally higher rate of
infection for a variety of reasons. Matching for origin was important to account for
genetic differences in rates of G6PD deficiency, and genetic and environmental
differences in rates of infection. We looked at whether infections were caused by
catalase positive or catalase negative organisms, because ofthe previously cited work
showing that G6PD deficient leukocytes may be similar to leukocytes obtained from
patients with chronic granulomatous disease in having impaired killing of catalase
positive organisms [5-7].
For Tables 5a, Sb, and Sc the differences in rates of G6PD deficiency between the
infected group and control "A" were analyzed by the chi-square method, and in all
cases the differences were found not to be statistically significant (p > .10). When
comparisons were made between each infected group and control "A" plus control
"B" patients, the value for differences between prevalence rate for G6PD deficiency
was significant (< .05) when all patients were considered or the groups were matched
for age. No separate comparisons with control "B" were made, owing to the small
number of subjects. In Table Sd, the group infected with catalase positive organisms
was compared with all control "B" patients. The differences were not statistically
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significant (p>.10). The catalase negative group had no G6PD deficiency, but
statistical analysis was not carried out because of the small size of the group.
Mortality data were collected but are incomplete because it was not possible to
follow patients remaining in hospitals after termination of the study. As far as is
known, none of the 12 G6PD deficient infected patients and 2 of the 43 G6PD
normal infected patients expired. There was no mortality in the control "A" group of
65 patients; in control "B," one ofthe 2 G6PD deficient and 3 ofthe 31 G6PD normal
patients failed to survive.
DISCUSSION
The frequency of G6PD deficiency in Iran has been studied by a number of other
investigators (refer to Table 6), and our results are in rough agreement. We did not
TABLE 4
Diagnosis in Control Patients
Number of Number
Diagnosis Patients Deficient
Control A
Closed trauma 25 4
Upper gastrointestinal hemorrhagea II 0
Disc herniation 10 2
Low back pain 4 1
Inguinal hernia 3 0
Minor congenital defect 3 0
Snake bite 3 1
Poisoning 3 0
Myocardial infarction 2 0
Burn contracture 1 0
65 8
Control B
Malignancy 6 1
Pneumoniab 4
No diagnosis 4 0
Viral infection 3 0
Steroid therapyc 3 0
Open trauma 2 0
Diabetes mellitus 2 0
Thalassemia I 0
Sickle cell anemia I 0
Chronic renal failure 1 0
Chronic heart failure I 0
Cirrhosis I 0
Rheumatic heart disease I 0
Tetanus 1 0
Renal stones I 0
Opium abuse I 0
33 2
aMalignancy ruled out.
bUnderlying causes (malignancy, hydatid cyst, TB) not ruled out.
cFor rheumatoid arthritis, vasculitis of unknown etiology, and Henoch-Schonlein purpura.176 CLARK AND ROOT
TABLE 5
Comparisons of G6PD Deficiency Rates*
Number of Number
Category Patients Deficient % Deficient
a. All Infected 55 12 22
Patients: Control "A" 65 8 12
Control "B" 33 2 6
Number of Number Number
Category Patients Villagers Deficient % Deficient
b. Matched for Infected 55 30 (55%) 12 22
Average Age: Control "A" 59 31 (59%) 7 12
(31 years) Control "B" 27 18 (67%) 2 7
Number of Average Number
Category Patients Age Deficient % Deficient
c. Matched for Infected 30 27 8 27
Origin: Control "A" 34 35 6 18
(Villagers Only) Control "B" 20 36 2 10
Number of Average Number
Category Patients Age Deficient % Deficient
d. By Etiologic Catalase + 22 31 5 23
Agent (Infected, Catalase - 4 50 0 0
Class I only):
Catalase +: Staphylococcus, Shigella, Salmonella, Brucella, Anthrax, Mycobacterium tuberculosis
Catalase -: Pneumococcus, Streptococcus, Actinomyces israelii
*When infected patients were compared to Control "A" patients the prevalence of G6PD deficiency was not
significantly different by X 2 analysis for all patients and groups matched for age and origin. When both Control "A"
and "B" patients were collectively compared to infected patients p values for G6PD deficiency noted were: <.05 (all
patients); <.05 (age matched); = . 10 (origin-matched).
TABLE 6
G6PD Deficiency in Iranian Males, Published Studies
Total Number Subject
Study % Deficient Subjects Characteristics Geographical Origin Religion
Bowman 1959 9.8 358 Hospital staff 275 from Shiraz, Moslem
[14] others scattered
Beaconsfield 1968 2.5 Yazd Moslem
[15] 25 192 Caspian littoral area Moslem
19-25 Kermanshah Moslem
9 Isfahan Moslem
Hedayat 1969 7 142 Blood donors Oman littoral area
[16] 9.9 557 and Teheran Moslem
12 108 hospital staff Teheran Jewish
Frischer 1973 9.8 409
[17]
A blank space signifies that the information was not available.G6PD DEFICIENCY AND INFECTION
have enough geographic distribution to confirm or refute Beaconsfield's [15] finding
of a higher incidence in previously malaria-infected areas. For the purpose of
comparison it is noteworthy that our patient group most closely resembles that
reported by Bowman for Shiraz [14].
Although the rates of G6PD deficiency were greater in infected than in control
groups, the differences were not significant when the control group was matched as
closely as possible for age, origin, and underlying diseases. When we included a
secondary control group with a variety of conditions that were not present in the
infected groups, the differences reached significance (p as low as .01 <p < .05, in
patients matched exactly for age). However, the secondary control group included
patients whose susceptibility to infection might have been increased due to disease
(other than G6PD deficiency) ortherapy; thus it was not strictly comparablewiththe
infected patient group. While it is noteworthy that none of these patients had
infections at the time of study, the prevalence of G6PD deficiency in control group
"B" was almost identical to control group "A." Nevertheless it could be argued that
an artificially low rate of G6PD deficiency in control "B" could occur if the
combination of G6PD deficiency and infection had led to an increased mortality in
this group before hospitalization. The same bias could occur if patients with G6PD
deficiency are less liable to develop the types of disorders present in control "B."
Either of these could explain why the differences in rate ofG6PD deficiency between
the infected and control groups increase when the secondary control group is
included, rather than a specific effect of G6PD deficiency on host defenses against
infection.
As noted, studies have shown that some G6PD deficient individuals are more
susceptible to infection only by catalase positive organisms [5-7]. Although the
prevalence of G6PD deficiency in patients infected with catalase positive organisms
was 22.7% as opposed to zero in those infected with catalase negative species, the
number of cases was too small to permit meaningful statistical analysis.
The average age of G6PD deficient patients with infection was 22 years; whereas
that of G6PD normal infected patients was 34 years. This was a highly significant
difference when analyzed by unpaired t-test (p < .001 < .005). One interpretation of
this observation is that the combination of G6PD deficiency and infection leads to
hospitalization at an earlier age than infection alone. This is consistent with the
hypothesis that G6PD deficient patients, once infected, have a more severe clinical
course. Data on mortality rates would be useful in further testing of this hypothesis,
but our data are insufficient for this purpose.
It is important to point out some ofthe limitations imposed by a study ofthis type.
First, the number of patients sampled was relatively small, and conceivably some of
the observed trends might become significant only in a large population study.
Second, we were not able to measureleukocyte G6PD levels, which would have made
our study more precise. Exact data on leukocyte G6PD activity would be particularly
relevant in establishing the clinical significance of defective pentose phosphate
metabolism in these cells. Third, a lack of optimal facilities and culturing techniques
within the particular hospitals prevented us from establishing every diagnosis of
infectious disease by culture, and sampling error might have been involved in those
that were. Fourth, it was not possible for us to document fully previous antibiotic
therapy, before hospitalization. Such treatment could be important in altering the
course ofinfectious diseases therebyaffecting hospitalization rates. Fifth, by selecting
mainly adult patients, we automatically minimized the chances of detecting very
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serious effects of G6PD deficiency on host resistance, which could result in early
mortality in childhood.
Finally, by selecting only hospitalized patients for study no information is gained
on the incidence of infection in G6PD deficient patients. Specifically, ongoing
hemolysis caused by infection or its treatment can lead to hospital admissions. By
concentrating only on patients with infections severe enough to result in hospitaliza-
tion, a true picture of a population's susceptibility to infection is not obtained.
Rather, one has only an estimate of the prevalence of serious infections, and this
estimate does not differentiate between infections made more severe by G6PD
deficiency (with or without hemolysis) and the reverse. Close monitoring of hemo-
lytic parameters before hospitalization would be required to determine whether this
is a source of bias, as well as perhaps producing information on the relationship of
hemolysis and infection; it would also provide a more accurate index ofthe incidence
of infection in normal and G6PD deficient subjects.
Another population study ofthe relationship ofG6PD deficiency and infection has
been published by Lampe et al. [18]. They compared rates of G6PD deficiency in
hospitalized Thai children with S. typhi, H. influenza B,pneumococcal, staphylococ-
cal, and tuberculous infections with outpatient controls. Taking only male patients,
their data show a difference in rate of G6PD deficiency between the infected group
and the controls approaching significance (p = .05), a finding rather similar to ours.
Their criteria for diagnosis for infectious disease were more rigorous than ours, but
their definition of G6PD deficiency is vague, and it is not clear how well the patients
and controls were matched for exact age and origin. Furthermore, like our study,
their method of patient selection precludes an estimate of the relative incidence rates
for infection in normal and G6PD deficient subjects.
Thus, while we can offer no final conclusions regarding the true relationship of
G6PD deficiency and the incidence of bacterial infections, a reasonable interpreta-
tion of data from these studies is that the two conditions do have meaningful
interactions. A thorough prospective analysis of large groups would be required to
pick up changes in infection incidence rates as well as severity, and to distinguish
among infections with different types of organisms. Such a project would be
potentially useful in providing additional knowledge of host defense mechanisms,
and may be clinically important for the millions of people with deficiency ofthis key
intracellular enzyme.
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